- Direct health care treatment for chronic health conditions totaled $1.1 trillion in 2016
- Total economic impact of $3.7 trillion in health care costs for chronic diseases in U.S. equivalent to nearly 20 percent of the U.S. gross domestic product
- Medical research into CBD-based therapies to treat epilepsy and other neuropsychiatric disorders holds great promise for affected individuals
- Development of CBD-based drug delivery platform that’s able to cross blood brain barrier via nasal route
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing innovative options for preventive and curative therapies using some of nature’s most compelling and creative pathways. Consider, for instance, PreveCeutical’s approach to delivering the healing properties of cannabidiol (“CBD”) in an innovative formula created specifically for administration via the nasal pathways. The company’s Sol-gel delivery platform is expected to be the first sustained-release, CBD-based nose-to-brain delivery system targeting a range of indications including epileptic seizures, inflammation, pain and other neurological disorders, an article discussing the research states (http://nnw.fm/6JA8f).
Chronic diseases and recurring health care issues are taking an increasingly bigger piece of the economic pie and disrupting the lives of many millions of people. U.S. health care costs for chronic diseases totaled $1.1 trillion in 2016 and balloon to $3.7 trillion when lost economic productivity is calculated into the total economic impact. According to a new report by Grand View Research, people around the world, along with their governments, are starting to take notice of alternative medicines and forms of therapy for chronic ailments and long-term pain (http://nnw.fm/y2GXP). The complementary and alternative medicine market is expected to generate revenue of more than $196 billion by 2025, the report states.
PreveCeutical is dedicated to developing preventative medical therapies based on the recognized health benefits of natural substances. A key component of its research and development program is the development of its sustained-release Sol-gel drug delivery platform, which would allow CBD-based therapies to become optimally bioavailable to patients dealing with a wide range of debilitating conditions.
The company’s Sol-gel drug delivery research program is being undertaken at the University of Queensland, Australia. The program is being conducted by PreveCeutical’s research partner, the Pharmacy Australia Centre of Excellence, and is led by PreveCeutical Chief Research Officer Dr. Harendra Parekh. Permits that allow the Pharmacy Australia Centre of Excellence at the University of Queensland to import cannabis plant material for research purposes have been secured from the Australian government’s Department of Health, and testing is underway (http://nnw.fm/Piz91).
Adding to the progression of the research is the recent signing of a non-disclosure agreement with a globally recognized drug delivery device manufacturer for the supply of spray devices for the Sol-gel CBD-based therapies. Engineered Sol-gels present an ideal platform for these therapies, as they are in‑solution upon administration and rapidly gel upon contact with mucosal tissue. Additionally, Sol-gels will provide for safer and more reliable drug delivery of agents, such as CBD, that are rapidly metabolized or that would benefit from direct nose-to-brain CNS (central nervous system) delivery, a news release states.
As noted in a Crystal Equity Research Report on PreveCeutical (http://nnw.fm/nB5PL), there is a growing global interest in alternative drug delivery methods, such as the company’s Sol-gel nose-to-brain delivery platform. PreveCeutical’s groundbreaking Sol-gel delivery system displays significant benefits to the patient, as it bypasses first pass metabolism in the stomach, intestines and liver, exhibiting a dramatic improvement in bioavailability. Sol-gels could offer a number of advantages over conventional liquid nasal sprays, including sustained delivery and therapeutic effects, reduced dosage requirements and reduced irritation and other negative side effects.
For more information, visit the company’s website at www.PreveCeutical.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
